Company profile for Syntrix Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Driven by our commitment to patients, we continue to push the boundaries of medicine and technology to develop new and better therapies where none existed before. We have a robust pipeline of product candidates in immuno-oncology and pain. In addition to development in our established areas of focus, we are also expanding – through both in-house development and strategic acquisitions and partnerships – to other disease a...
Driven by our commitment to patients, we continue to push the boundaries of medicine and technology to develop new and better therapies where none existed before. We have a robust pipeline of product candidates in immuno-oncology and pain. In addition to development in our established areas of focus, we are also expanding – through both in-house development and strategic acquisitions and partnerships – to other disease areas where there are unmet needs.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
215 Clay Street NW, Suite B-5, Auburn, WA 98001
Telephone
Telephone
253-833-8009
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/first-in-class-investigational-sx-682-demonstrates-single-agent-efficacy-in-patients-with-hypomethylating-agent-failure-myelodysplastic-syndromes-301699265.html

PRNEWSWIRE
09 Dec 2022

https://www.prnewswire.com/news-releases/syntrix-completes-initial-sx-682-dosing-in-broad-phase-12-cancer-trial-campaign-now-encompassing-5-solid-cancer-types-plus-myelodysplastic-syndromes-301160630.html

PRNEWSWIRE
26 Oct 2020

https://www.prnewswire.com/news-releases/syntrix-discovers-desmetramadol-is-g-protein-biased-opioid-receptor-agonist-300998555.html

PR NEWSWIRE
04 Feb 2020

https://www.prnewswire.com/news-releases/syntrix-pharmaceuticals-to-present-positive-desmetramadol-trial-results-at-the-2019-pain-management-summit-300949283.html

PR NEWSWIRE
31 Oct 2019

https://www.prnewswire.com/news-releases/syntrix-pharmaceuticals-announces-publication-of-positive-double-blind-clinical-trials-showing-desmetramadol-has-the-analgesic-and-side-effect-profile-of-tramadol-without-its-metabolic-liabilities-300861610.html

PR NEWSWIRE
04 Jun 2019

https://www.prnewswire.com/news-releases/syntrix-wins-3-4m-nih-grant-to-conduct-phase-12-trial-of-sx-682-in-myelodysplastic-syndrome-300788624.html

PR NEWSWIRE
04 Feb 2019

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty